Under a strategic collaboration agreement, the companies will involve in the discovery, development and commercialisation of novel Bicycle Therapeutics-based immuno-oncology therapies. The deal allows Bicycle to explore its
FETROJA, which was approved by the U.S. Food and Drug Administration on November 14, 2019, is the first approved antibiotic that functions as a siderophore and has the
Under the research collaboration, the companies will evaluate Clover’s protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) with GSK’s pandemic adjuvant system. GSK’s pandemic adjuvant system will help further assess
Committed to advancing the research and development process and clinical utility of biopharmaceutical companies’ novel biomarker-driven oncology drug, Genetron Health has already formed partnerships with dozens of leading
Claimed to be the first FDA-approved intravenous (IV) treatment for migraine prevention, the Vyepti will be available from April and the recommended dose is 100mg for every three
“These designations for FORMA’s lead clinical asset underscore the FDA’s continued recognition of the needs of patients with SCD,” said Frank Lee, chief executive officer of FORMA Therapeutics.
As per terms of the deal, Immatics will secure an upfront payment of up to $50m from GSK for two initial programmes. Immatics has an option to secure
DSM developed and patented a method to produce a highly pure form of the API. Included in the acquisition are patents, trademarks, trade secret manufacturing processes, analytical methods,
The breakthrough therapy status enables Padcev plus Keytruda combination to treat patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in
Data supporting these Fast Track designations were based on an open-label, multicenter Phase 1 clinical trial of ALX148 in combination with pembrolizumab or trastuzumab. “FDA’s decision to grant
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.